Publications by authors named "Eric Sheldon"

Claim this Profile
S
Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
Sylvie Pichon, Annick Moureau, Celine Petit, Judith L Kirstein, Eric Sheldon

Vaccine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
D Gray Heppner, Tracy L Kemp, Brian K Martin, William J Ramsey, Richard Nichols, Eric A Sheldon

Lancet Infect Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Anuradha Madan, Harry Collins, Eric Sheldon, Louise Frenette, Laurence Chu

Vaccine· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Anuradha Madan, Murdo Ferguson, Eric Sheldon, Nathan Segall, Laurence Chu

Vaccine· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
C Buddy Creech, Robert W Frenck, Eric A Sheldon, David J Seiden, Martin K Kankam

Vaccine· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
Robert W Frenck, C Buddy Creech, Eric A Sheldon, David J Seiden, Martin K Kankam

Vaccine· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
Chan R Beals, Radha A Railkar, Andrea K Schaeffer, Yotam Levin, Efrat Kochba, Eric A Sheldon

Lancet Infect Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Judith Falloon, Fei Ji, Craig Curtis, Stephan Bart, Eric Sheldon

Vaccine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Robert J Hopkins, Gurdyal Kalsi, Victor M Montalvo-Lugo, Mona Sharma, Yukun Wu, Eric A Sheldon

Vaccine· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.
Eric Sheldon, Nicholas Kitchin, Yahong Peng, Joseph Eiden, William Gruber

Vaccine· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
Eric Sheldon, Martin Schwickart, Jing Li, Keunpyo Kim, Sarah Crouch

Adv Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
Robert J Hopkins, Cris Howard, Ericka Hunter-Stitt, Paulina E Kaptur, Brett Pleune, Eric Sheldon

Vaccine· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
Eric A Sheldon, Robert Jeanfreau, Joseph A Sliman, Supoat Charenkavanich, Matthew D Rousculp

Influenza Other Respir Viruses· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Dorothee Kieninger, Eric Sheldon, Wen-Yuan Lin, Chong-Jen Yu, Jose M Bayas

BMC Infect Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Robert J Hopkins, Nancy F Daczkowski, Paulina E Kaptur, Derek Muse, Eric Sheldon

Vaccine· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.
George Risi, Louise Frenette, Joanne M Langley, Ping Li, Dennis Riff, Eric Sheldon

Vaccine· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
David N Taylor, John J Treanor, Eric A Sheldon, Casey Johnson, Scott Umlauf

Vaccine· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
Eric A Sheldon, Howard Schwartz, Qin Jiang, Peter C Giardina, John L Perez

Hum Vaccin Immunother· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
Murdo Ferguson, George Risi, Matthew Davis, Eric Sheldon, Mira Baron

J Infect Dis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
Stan L Block, Tingting Yi, Eric Sheldon, Filip Dubovsky, Judith Falloon

Vaccine· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.
George Risi, Louise Frenette, Joanne M Langley, Ping Li, Dennis Riff, Eric Sheldon

Vaccine· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.
Joanne M Langley, George Risi, Michael Caldwell, Larry Gilderman, Bruce Berwald, Eric Sheldon

J Infect Dis· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Joanne M Langley, Louise Frenette, Linda Ferguson, Dennis Riff, Eric Sheldon

J Infect Dis· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.
Eric Plennevaux, Eric Sheldon, Mark Blatter, Mary-Kate Reeves-Hoché, Martine Denis

Lancet· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Alan Kivitz, Michael Fairfax, Eric A Sheldon, Qinfang Xiang, Beverly A Jones

Clin Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis